Since I am using Suno to develop musical whims, looking further into the company has merit. Below captures what I have found so far:
Below is embedded a song named “Home Again” from Suno, not of my making:
Category: Uncategorized (Page 1 of 71)
Dialysis-wise, things are going along without any glitches. I’ve had some time to catch up on outside chores and play around with some new-to-me AI software, which is what this blog is about.
We will use Suno as a show-and-tell.
Suna AI is an innovative music creation platform that blends artificial intelligence with human creativity, opening new possibilities for musicians, producers, and casual creators alike. Designed to generate, remix, and refine songs across a variety of genres, Suna AI lets users compose original tracks simply by describing the mood, style, or instrumentation they want. Its intuitive interface and advanced sound modeling make it accessible to both beginners exploring music for the first time and to professionals seeking fresh inspiration. What sets Suna AI apart from traditional digital audio tools is its ability to understand artistic intent—transforming plain-language prompts into entirely produced, ready-to-share music that captures emotion and nuance with surprising depth.
A week or so ago, I blogged about the song “Dance With Me Henry,” released in 1955 when I was a junior in high school in Springfield, Ohio. In this song, Henry was chastised for not responding to overtures from his female dance partner. That was 70 years ago, and there has been no response from Henry. I used Suno and composed a response, which is embedded below. It is not perfect. At times, Henry’s vocals get interchanged with the female voice and vice versa, which I could not undo. But you will get the idea. Enjoy.
My new Oncologist’s office came through for me, and I have an appointment to assess if this treatment is for me on 1 December 2025 at 0900. I have filled out the patient data online, which was monumental – it took over an hour, so check-in should be short. I have browsed their website and conducted further Perplexity research on the subject. Below is the most concise information I have found to date and is included herein for your information:
The following is quoted from https://jsstd.org/immunotherapy-in-skin-cancers-a-narrative-review/#S2_2
“The immune system has inbuilt checkpoints to prevent destruction of ‘self’ antigens. Cancer cells sometimes make use of these checkpoints to protect themselves from the immune response. Checkpoint inhibitors, as the name suggests, target the checkpoint proteins and enable the immune system to more effectively recognize and act on the cancer cells.
CART: T cells are taken from the patient, and genes for receptors related to the cancer (chimeric antigen receptor) are added to these cells. When reinfused into the patient’s blood, these modified T cells bind to the cancer cells and kill them.
Immunotherapy has been used in virtually all types of skin cancers, both melanoma, and non-melanoma.[1–12]
Usually, immunotherapy starts showing response within a few weeks. Candidate selection for immunotherapy depends on various factors like type of cancer, stage of cancer, biomarkers expressed by cancer cells, and evolving treatment guidelines. Programmed cell death receptor ligand 1 (PD-L1) expression, high microsatellite instability or high tumor mutational burden and advanced cancers unfit for other treatment options are all regarded as candidates for immunotherapy. Though immunotherapy is mainly indicated for the treatment of advanced cancers, many trials have been conducted in the treatment of non-metastatic, early-stage cancers for the achievement of prolonged outcome without the long-term side effects associated with chemotherapy. There is no exact cut-off point for stoppage of these drugs. Duration depends on the response to each drug and the development of side effects that require temporary cessation. Besides this, the high cost (running into lakhs) is a major limiting factor for continuing treatment.[13]+”
One of the goals of my input to our stock portfolio is to have sufficient cash flow from interest and dividends alone to support my wife when I punch out. I use this term not as in an injection from an aircraft, but as leaving life as it’s known on earth. Recently, I went to work, rationalizing several stocks and reinvesting them in HRZN, which currently has an over 20% return. This blog takes you through how I checked HRZN out before pushing the go button on the investment, which currently stands at 3000 shares.
Our broker, Schwab, offers many research-oriented pathways. This is the first area I explored upon the start of my initial due diligence. One such report on HRZN in PDF format is presented below for information. I gleaned from this type of info that, in general, the purchase of HRZN was not recommended, but being a contrarian, I noted that the price appeared to be bottoming out. This, in and of itself, presents an opportunity. I also observed that HRZN was a consistent payer of its monthly dividend, without any reductions. To me, this was an opportunity to buy at or near the dip and maximize potential returns.
I then turned to Perplexity.ai with numerous prompts.
I am attempting to maximize short-term dividend returns. Would you buy HRZN, all risks aside
Suppose the sole objective is to maximize dividend return in the short term, and all risks are ignored. In that case, HRZN is an unusually strong candidate based on its current forward yield (about 20% at $0.11/month and ~$6.68/share) and its consistent history of monthly payouts. This high yield is well above that of most dividend stocks or funds, and monthly compounding via DRIP further enhances short-term income.
However, such high yields are rarely sustainable and often signal underlying risk, such as the potential for dividend cuts, portfolio losses, or share price erosion. But with risk disregarded, HRZN offers unusually rapid dividend accumulation and cash yield, making it one of the best vehicles for short-term dividend maximization among widely available equities.
I am OK with the risks involved, having owned HRZN several times previously and having bought 3000 shares at various prices, as low as $6.44. Given the investment of slightly over $18,000, I then turned back to Perplexity with additional queries. One is shown in the PDF below:
At the point I had accumulated 1000 shares, I did another query about accumulation as shown in the PDF below;
Of interest to me is how long it will take my investment to double? See PDf below.
I invested most of my money in HRZN before its ex-dividend date in November, so I should receive the first dividend payment shortly. The price has eroded somewhat to the point I’m currently down a couple of grand, but ups and downs are part of the game. I am in this for dividends, which are independent of price fluctuations once purchased.
As a fifteen-year-old in 1955, a song titled “The Wallflower” started playing on the radio. Soon, a title “Roll With Me Henry” was announced, followed by “Dance With Me Henry.” Predating these renditions was an often-banned song by The Midnighters named “Work With Me Annie.” The two had similar sounds and messages. I’ve embedded the original version below, followed by Perplexity’s take on what was happening in the original song. Keep in mind that my first name is Henry, so I had more than a passing interest in this song at 15.
“Dance With Me Henry” is a song originally recorded in 1955 by Etta James and her vocal group, The Peaches, under the title “The Wallflower (Roll With Me Henry)”. The song was written by Etta James, Johnny Otis, and Hank Ballard as a response—a so-called “answer song”—to Ballard’s earlier hit “Work With Me Annie”. The name “Henry” in the lyrics is not a specific person but rather a stand-in for a male dance partner. The song uses playful call-and-response and flirtatious lyrics, which, for the time, were considered suggestive.wikipedia+6
Song Origins and History
- The original was recorded by Etta James and The Peaches, with uncredited responses by R&B singer Richard Berry.udiscovermusic
- It was released on Modern Records and became a No. 1 R&B hit for several weeks in 1955.udiscovermusic
- The song’s bold sexual innuendo led to its title being changed from “Roll With Me Henry” to “The Wallflower” to avoid FCC censorship.culturesonar+2
Covers and Popularity
- Pop singer Georgia Gibbs covered the track as “Dance With Me Henry” (sometimes listed as “Dance With Me Henry (Wallflower)”), sanitizing the lyrics for the pop market.facebook+1
- Gibbs’ cover became a No. 1 hit on the mainstream charts, eclipsing James’ original in crossover reach. youtubefacebook
- Etta James later covered the pop version herself.culturesonar
Musical Style and Legacy
- The song bridged blues, gospel, and early rock and roll, influencing later artists and genres.culturesonar+1
- James’s assertive vocals signaled a breakthrough for female empowerment in R&B and rock.culturesonar
- It was later featured in the movie “Back to the Future” and inducted into the Grammy Hall of Fame in 2008.udiscovermusic+1
The “Henry” Character
- “Henry” is not a real person but represents the desired male partner—or foil—addressed by the narrator in call-and-response fashion.songfacts+2
- In the original, Richard Berry plays Henry in vocal interchanges with James.udiscovermusic
Groups and Notable Artists
- Original: Etta James and The Peaches (with Richard Berry responding as Henry).udiscovermusic
- Songwriters: Etta James, Johnny Otis, Hank Ballard.backtothefuture.fandom+2
- Notable cover: Georgia Gibbs on Mercury Records.youtubefacebook
The song’s story is a classic example of how rhythm & blues tracks crossed over to pop audiences—with altered lyrics and broader appeal—while the originals often paved the way for significant musical and cultural shifts.culturesonar+1
- https://en.wikipedia.org/wiki/The_Wallflower_(Dance_with_Me,_Henry)
- https://www.culturesonar.com/etta-james-and-roll-with-me-henry/
- https://www.facebook.com/groups/DoYouRememberThe60sFanClub/posts/2226004974458790/
- https://www.udiscovermusic.com/stories/etta-james-the-wallflower-song/
- https://backtothefuture.fandom.com/wiki/The_Wallflower_(Dance_with_Me,_Henry)
- https://www.youtube.com/watch?v=xSJTWUo-WWQ
- https://www.britannica.com/topic/The-Wallflower
- https://www.facebook.com/groups/824194430969202/posts/9367835869938306/
- https://www.facebook.com/groups/824194430969202/posts/on-june-23-1955-we-were-hearing-dance-with-me-henry-by-georgia-gibbs-sanitizing/9848441101877778/
- https://www.reddit.com/r/78rpm/comments/1osh51e/ronnie_stevens_dance_with_me_henry_jack_arthur/
- https://www.songfacts.com/lyrics/etta-james/the-wallflower
- https://open.spotify.com/track/5neyzFjnykdFbcmMmTGSzZ
- https://en.wikipedia.org/wiki/Dance_with_Me,_Henry
- https://www.youtube.com/watch?v=Ta5400IjRQA
It came out of left field, so to speak. Had our visit with the new dermatologist at Bear. They were able to obtain our old records from our previous one and, together with the pathologies recently taken, decided I should see a recommended local oncologist to try a relatively new treatment. The new treatment involves kicking my immune system into high gear regarding cancer cells through a system of injecting specific drugs and letting my own body do its thing. Below is what Perplexity has to say about this treatment:
Immunotherapy injections for skin cancer work by stimulating the body’s natural defenses to seek out and destroy cancer cells. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy activates or enhances components of the immune system to recognize cancer as a threat and target it.cancerresearch+1
Immune Checkpoint Inhibitors
A major class of injectable immunotherapies is called immune checkpoint inhibitors. Cancer cells often use “checkpoints” to evade immune attack—proteins like PD-1 and PD-L1 act as brakes on immune responses. Drugs such as pembrolizumab and nivolumab block these checkpoints, releasing the brakes and allowing T cells to recognize and kill cancer cells.jsstd+1
Oncolytic Virus and Immune Activation
Other immunotherapy injections, such as talimogene laherparepvec (T-VEC), involve injecting a modified virus directly into skin tumors. This virus infects and bursts the cancer cells, releasing tumor antigens (identifying proteins) that alert the immune system. T-VEC also attracts and matures dendritic cells, which help teach the immune system to recognize and attack melanoma not just in the injected tumor, but throughout the body.oncodaily+2
Cytokine and Receptor Agonists
Certain drugs or creams, like imiquimod, stimulate immune pathways by activating toll-like receptors on immune cells. This leads to the production of cytokines such as interferon-alpha and TNF-alpha, which further activate T cells and other immune cells to attack the tumor.oncodaily+1
Impact and Expansion
These immunotherapy strategies have proven especially effective for advanced or metastatic forms of melanoma and other skin cancers by directing the patient’s own immune system to seek and destroy cancer across the body, sometimes with durable, long-term responses.cancer+1
In summary, immunotherapy injections activate a cascade of immune events—lifting restrictions on immune cells, signaling distress to the immune system, or directly presenting tumor antigens—to unleash the body’s own ability to fight and clear skin cancer.jsstd+2
Of interest to me is whether patients on peritoneal dialysis can receive this immune-based treatment? Perplexity suggests:
Yes—patients on dialysis, including peritoneal dialysis (PD), can receive pembrolizumab or nivolumab in many cases, because these large monoclonal antibody drugs are not cleared by dialysis and generally do not require dose adjustment in patients with renal failure. That said, careful monitoring for immune-related side effects is essential, and solid-organ transplant recipients face a significant risk of graft rejection with PD-1 inhibitors.pmc.ncbi.nlm.nih+2
Why dialysis usually isn’t a barrier
- Pembrolizumab and nivolumab are IgG monoclonal antibodies with high molecular weight, so they are not removed by hemodialysis; timing relative to dialysis is typically not critical.pmc.ncbi.nlm.nih+1
- Pharmacokinetics of PD-1 inhibitors show no clinically meaningful effect of renal dysfunction on clearance, so standard dosing is generally used in end-stage kidney disease (ESKD).academic.oup+1
- Case reports and series document the safe use of pembrolizumab at standard doses in dialysis patients, with responses and manageable toxicities reported. pmc.ncbi.nlm.nih+2
Peritoneal vs hemodialysis
- Most published experience is in hemodialysis, but the same principles apply to PD: peritoneal dialysis does not clear monoclonal antibodies, so dose adjustment is not expected.academic.oup+1
- Given limited PD-specific data, oncologists typically extrapolate from hemodialysis evidence and pharmacology, using standard dosing and close monitoring.pmc.ncbi.nlm.nih+1
Important cautions
- Solid-organ transplant: PD-1 inhibitors can precipitate acute allograft rejection; documented cases include renal transplant rejection soon after nivolumab, and risk is considered high for any anti-PD-1 therapy.jitc.bmj
- Immune-related adverse events (irAEs): Kidney inflammation (e.g., acute interstitial nephritis), thyroid dysfunction, colitis, pneumonitis, and others can occur and require prompt diagnosis and immunosuppression when moderate to severe.pmc.ncbi.nlm.nih
- Coordination of care: Close collaboration between oncology and nephrology is recommended to track labs, manage fluid status, and distinguish irAEs from dialysis-related symptoms.academic.oup+1
Practical approach discussed in reports
- Use standard dosing regimens (e.g., pembrolizumab 200 mg q3w or 400 mg q6w; nivolumab per label) without routine dose reduction for dialysis.sciencedirect+2
- Dialysis timing: Not usually necessary to coordinate dosing with dialysis sessions, though some clinicians administer after dialysis for convenience and consistency.revistanefrologia+1
- Monitor closely: Baseline and periodic labs (CBC, CMP, thyroid panel), urinalysis if residual kidney function, and early evaluation of new symptoms to detect irAEs.academic.oup+1
Bottom line: For PD patients without a functioning transplant, pembrolizumab and nivolumab are often feasible at standard doses, with vigilance for immune toxicities and multidisciplinary oversight; transplant recipients require individualized risk–benefit discussions due to rejection risk.jitc.bmj+2
https://onlinelibrary.wiley.com/doi/10.1155/2018/1623957
https://pmc.ncbi.nlm.nih.gov/articles/PMC5051445/
https://academic.oup.com/ckj/article/14/9/2012/6272220
https://pmc.ncbi.nlm.nih.gov/articles/PMC7467783/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8958579/
https://karger.com/cro/article/15/1/187/823179/Use-of-Pembrolizumab-in-End-Stage-Renal-Disease-A
https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e14553
https://jitc.bmj.com/content/4/1/64
https://www.sciencedirect.com/science/article/pii/S2666621925000304
https://www.keytrudahcp.com/dosing/options/
https://clinicaltrials.gov/study/NCT07117409
https://www.sciencedirect.com/science/article/pii/S2468294221000472
- https://oncodaily.com/oncolibrary/immune-oncology/immunotherapy-for-skin-cancer
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6626298/
- https://onlinelibrary.wiley.com/doi/full/10.1002/aac2.70000
- https://www.sciencedirect.com/science/article/pii/S0305737224001774
- https://jsstd.org/immunotherapy-in-skin-cancers-a-narrative-review/
- https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.880876/full
- https://ecancer.org/en/news/26227-research-reveals-how-melanoma-and-other-tumours-succeed-in-hiding-and-resisting-immunotherapy
- https://www.cancerresearch.org/blog/difference-cancer-immunotherapy-and-chemotherapy
- https://www.cancer.org/cancer/types/basal-and-squamous-cell-skin-cancer/treating/immunotherapy.html
- https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
Monday, I received a call from Bare Dermotologist, the outfit that I recently went to concerning the massive amounts of skin cancers on my head and neck. First visit, they extracted four samples, three from the back of my neck, and one from my right finger; they all came back either basal or squamous cancers. The one on my right finger started as a viral wart. The literature on viral warts suggests, under certain circumstances, they may turn cancerous. They also changed the appointment time to 1120, during which my options will be presented. If I choose radiation, which I probably will, treatments should take place then.
The second accomplishment on Monday was to sell a couple of BDC stocks that were returning around 12% and used the proceeds to buy more HRZN stock. We now hold 4000 shares of HRZN—more about this in Friday’s blog.
Today, I’m going to provide more information on something I am experiencing, Viral Warts. Tomorrow I have a real go-around with my new dermatologist, where we should start to have some of the numerous cancers on and around my head treated. If I’m still alive (grin), I will relate the experience. Friday, I have, IMHO, a really great Financial Friday in mind for you. As in the past, it will be based on my actual investment activity, how I decided what to invest in, and what the investment’s future may yield. Wednesday and Thursday are open at this point, and on Sunday, when I’m writing this blog. I just picked up on the Grammarly AI writing assistant with Black Friday half-price deal, so standby.
During last week’s meeting with my dialysis team, we (my wife and I) brought up the subject of Viral Warts and didn’t get anywhere or any satisfaction. We don’t know if they had not encountered them previously or if it was just a lack of empathy. At times, they can be stoic at best, probably hardened by their experiences, which is understandable to a degree.
So, aside from being diagnosed with this new affliction, I wanted to know more about the population of dialysis patients “blessed” with viral warts. I turned to Perplexity.ai with the following prompt and results. Along the way in researching this topic, I learned that I fit just about all of the If then -> warts criteria: age, sex, time on dialysis, etc.
Prompt: What are the characteristics of ESRD patients who develop renal warts?
Most descriptions of “who gets warts” in kidney disease are about transplant recipients, so the data for ESRD itself are thinner; however, a pattern emerges from dialysis and CKD skin‑series and from HPV‑cancer data. In ESRD, warts seem to occur in patients who share the general ESRD risk profile (uremic immune dysfunction, long disease duration) plus the usual HPV risk factors seen in the general population.pmc.ncbi.nlm.nih+3
Demographic tendencies
- Middle‑aged and older adults: HPV‑related cancers in ESRD peak around ages 50–64, implying that persistent HPV infection (and thus warts) is most relevant in this age band.pmc.ncbi.nlm.nih
- Both sexes are affected, with some signals by sex: For HPV‑related cancers in ESRD, female sex is a risk factor (IRR ≈ 2.1 vs ESRD men). For cutaneous warts specifically, one CKD skin‑disease review notes common warts among ESRD patients without a strong sex skew. Still, detailed sex‑stratified wart data are rarely reported.pmc.ncbi.nlm.nih+2
Renal and dialysis‑related characteristics
- Advanced, long‑standing renal failure: Reviews of cutaneous disease in CKD/ESRD emphasize that viral infections including common warts are a recognized problem mainly in patients with advanced uremia and on long‑term renal replacement therapy.actasdermo+1
- Dialysis, any modality: Hemodialysis cohorts show low but definite wart prevalence (a few percent in series of 100–200 patients), and authors note that “human papillomavirus–induced warts are common in kidney disease,” reflecting the background uremic immune defect rather than a specific dialysis type. Peritoneal dialysis appears similar or slightly less studied rather than clearly different.pmc.ncbi.nlm.nih+1
- Heavy comorbidity burden: ESRD patients with higher overall comorbidity have more infection‑related complications in general. However, for HPV‑related cancers specifically, comorbidity level was not a clear additional risk factor once ESRD status itself was accounted for.karger+1
Immune and virologic factors
- Uremic immune dysfunction: Reviews of skin disease in CKD highlight that ESRD patients have impaired cellular immunity, altered T‑cell and antigen‑presenting cell function, and chronic inflammation, which collectively predispose to chronic viral skin infections such as warts.actasdermo+2
- Difficulty clearing HPV: The same immune defects that raise cancer risk also make HPV infections more persistent, which is why ESRD cohorts show a 2–2.5‑fold higher incidence of HPV‑related cancers compared with the general population. Persistent high‑risk HPV infection is biologically linked to both genital warts (from certain types) and HPV‑related dysplasia and cancer.frontiersin+1
- General HPV risk factors still matter: Systematic reviews of cutaneous warts (in mixed populations) note that smoking, close personal contact, communal environments, and atopy increase wart risk. For HPV‑associated cancers (which track high‑risk HPV exposure), smoking, alcohol, and HIV infection are important cofactors. These same factors likely identify the subgroup of ESRD patients more prone to clinically evident or persistent warts.onlinelibrary.wiley+2
Clinical wart pattern in ESRD
- Low absolute prevalence, but higher than normal: Skin‑series in hemodialysis show warts in only a few percent of patients, yet this is still more frequent than in matched healthy controls, and authors explicitly list viral warts among the “most frequent viral infections” in CKD skin disease.healthcare-bulletin+2
- Stubborn, chronic lesions: When warts appear in ESRD, clinicians describe them as more persistent and sometimes refractory, mirroring the broader experience of infections in ESRD patients.pmc.ncbi.nlm.nih+1
- Association with other skin problems of CKD: Patients with xerosis, pruritus, pigment changes, and other CKD skin abnormalities are the same broad group in which warts are reported; warts are one item in this constellation rather than a distinct phenotype.ijdvl+2
Putting this together for “who gets warts” in ESRD
ESRD patients who develop warts typically have:
- Long‑standing, advanced renal failure on dialysis with uremic immune dysfunction.actasdermo+1
- Usual HPV exposure/risk factors (sexual exposure, close skin contact, sometimes smoking or other co‑morbid risks).pubmed.ncbi.nlm.nih+2
- Age in mid‑ to later adulthood, where persistent HPV infection and HPV‑related disease are most evident.pmc.ncbi.nlm.nih
Unlike the transplant setting, there is no sharply defined “wart phenotype” (for example, specific drugs), but rather a background of modest immune fragility in ESRD that makes the usual HPV exposures more likely to result in chronic, slow‑to‑clear warts.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3710213/
- https://onlinelibrary.wiley.com/doi/10.1111/pde.16002
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8061480/
- http://www.actasdermo.org/en-skin-manifestations-chronic-kidney-disease-articulo-S0001731015002720
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4299702/
- https://karger.com/bpu/article/47/1-3/259/329355/Recognizing-Common-Skin-and-Soft-Tissue-Infections
- https://www.actasdermo.org/en-skin-manifestations-chronic-kidney-disease-articulo-S1578219015002346
- https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.1057454/full
- https://pubmed.ncbi.nlm.nih.gov/32503931/
- https://journals.sagepub.com/doi/abs/10.1136/jim-2019-001262
- https://www.healthcare-bulletin.co.uk/article/volume-14-issue-3-pages870-878-ra/
- https://ijdvl.com/cutaneous-manifestations-in-patients-with-chronic-renal-failure-on-hemodialysis/
- https://www.ijord.com/index.php/ijord/article/view/1234
- https://www.sciencedirect.com/science/article/pii/S1600613522089079
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772021
- https://emedicine.medscape.com/article/1094846-overview
- https://www.semanticscholar.org/paper/Incidence-and-risk-factors-for-HPV-associated-in-Han-Waller/fe6a798835199fa86e050e34bcdb696514e80486
- https://onlinelibrary.wiley.com/doi/10.1111/ajt.14181
- https://nigjdermatology.com/index.php/NJD/article/download/31/6/121
- https://www.ectrx.org/detail/archive/2019/17/1/0/31/0
- https://academic.oup.com/ndt/article/32/1/132/2931147
I recently read in a WSJ article that companies in the nascent industry involving quantum computing are of great interest to investors. Several companies were listed as competing in the space, including QBTS. I then went to Perplexity and instructed it to accomplish Deep Research on this company. The embedded PDF below is the resultant report. Very well done and in great depth that directly and specifically addresses the questions posed in my prompt, as you may ascertain.
Prompt: Do deep research into the quantum stock QBTS: should I buy into it or not? If I buy, how many shares?
Please turn up your audio, watch the embedded video below, then read the following text about the video.
Otis Lee Booker is the fictional persona behind “My Baby Loves Biscuits More Than Me,” a song crafted to emulate an extremely rare 1939 Delta blues recording, but actually brought to life using AI-driven remastering and storytelling techniques in recent years. While some project pages and videos claim the track was rescued from old shellac discs and lost sessions in the Mississippi Delta, official disclaimers on these recent releases confirm that the backstory and character are creative inventions—the music is real, but the artist and his history are fabricated for the sake of tribute and parody.
The song itself captures the humor, sorrow, and grit of Depression-era blues through a raw, playful tale of heartbreak and food, sung in a style that channels legendary Delta blues traditions. The internet reaction and write-ups treat Otis Lee Booker as a tongue-in-cheek homage to lost blues musicians whose lives and recordings have faded into legend, with cover versions and remix projects further amplifying the fictional lore.
Separately, records exist for a real person named Otis Lee Booker Sr. (1962–1994) from Moss Point, Mississippi, but there is no evidence connecting this individual to blues music or the AI-driven song project described above.
